{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:27Z","timestamp":1786119267955,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/gme.0b013e3181ac0cc1","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T03:17:35Z","timestamp":1262661455000},"page":"140-144","source":"Crossref","is-referenced-by-count":14,"title":["Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor \u03baB in women with postmenopausal osteoporosis"],"prefix":"10.1097","volume":"17","author":[{"given":"Rebeca","family":"Reyes-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mu\u00f1oz-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Fern\u00e1ndez","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mezquita-Raya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Garc\u00eda Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"de Dios Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20210227","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long term risedronate on quality and bone turnover in women with postmenopausal osteoporosis.","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"R2-25-20210227","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF02409454","article-title":"Role of osteoblasts in hormonal control of bone resorption-a hypothesis.","volume":"33","author":"Rodan","year":"1981","journal-title":"Calcif Tissue Int"},{"key":"R3-25-20210227","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/endo.137.6.8641182","article-title":"Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.","volume":"137","author":"Vitte","year":"1996","journal-title":"Endocrinology"},{"key":"R4-25-20210227","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s001090100226","article-title":"Role of receptor activator of nuclear factor-B ligand and osteoprotegerin in bone biology.","volume":"79","author":"Hofbauer","year":"2001","journal-title":"J Mol Med"},{"key":"R5-25-20210227","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R6-25-20210227","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women.","volume":"16","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R7-25-20210227","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-25-20210227","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/emm.2002.21","article-title":"Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.","volume":"34","author":"Kim","year":"2002","journal-title":"Exp Mol Med"},{"key":"R9-25-20210227","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF- converting enzyme (TACE).","volume":"1","author":"Pan","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R10-25-20210227","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/eje.0.1480527","article-title":"Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.","volume":"148","author":"Valleala","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"R11-25-20210227","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.10834","article-title":"Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.","volume":"48","author":"Alvarez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R12-25-20210227","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bone.2004.11.004","article-title":"Interleukin 6 and osteoprotegerin system in Paget's disease of bone: relationship to risedronate treatment.","volume":"36","author":"Mossetti","year":"2005","journal-title":"Bone"},{"key":"R13-25-20210227","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.2003.04657.x","article-title":"Pamidronate is an affective treatment for osteoporosis in patients with -thalassaemia.","volume":"123","author":"Voskaridou","year":"2003","journal-title":"Br J Haematol"},{"key":"R14-25-20210227","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporos Int"},{"key":"R15-25-20210227","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s00198-002-1348-1","article-title":"Assessment of prevalent and incident vertebral fractures in osteoporosis research.","volume":"14","author":"Genant","year":"2003","journal-title":"Osteoporos Int"},{"key":"R16-25-20210227","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s00198-005-1844-1","article-title":"The contribution of serum osteoprotegerin on bone mass and vertebral fractures in postmenopausal women.","volume":"16","author":"Mezquita-Raya","year":"2005","journal-title":"Osteoporos Int"},{"key":"R17-25-20210227","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2265.2004.02179.x","article-title":"Circulating osteoprotegerin and receptor activator of NF-B ligand system are associated with bone metabolism in middle aged males.","volume":"62","author":"Oh","year":"2005","journal-title":"Clin Endocrinol"},{"key":"R18-25-20210227","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00198-004-1699-x","article-title":"Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.","volume":"16","author":"Indridason","year":"2005","journal-title":"Osteoporos Int"},{"key":"R19-25-20210227","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03040334","article-title":"Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover or fracture status.","volume":"115","author":"Fahrleitner-Pammer","year":"2003","journal-title":"Wien Klin Wochenschr"},{"key":"R20-25-20210227","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1210\/jc.2002-020396","article-title":"Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.","volume":"87","author":"Rogers","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-25-20210227","first-page":"631","article-title":"Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.","volume":"86","author":"Browner","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-25-20210227","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"Circulating osteoprotegerin and receptor activator for nuclear factor B ligand: clinical utility in metabolic bone disease assessment.","volume":"90","author":"Rogers","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-25-20210227","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s001980200045","article-title":"Correlates of osteoprotegerin levels in women and men.","volume":"13","author":"Khosla","year":"2002","journal-title":"Osteoporos Int"},{"key":"R24-25-20210227","first-page":"3607","article-title":"Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.","volume":"25","author":"Zojer","year":"2005","journal-title":"Anticancer Res"},{"key":"R25-25-20210227","first-page":"3162","article-title":"Osteoprotegerin serum levels in men: correlation with age, estrogen and testosterone status.","volume":"86","author":"Szulc","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R26-25-20210227","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jama.291.9.1108","article-title":"Soluble RANKL and risk of nontraumatic fracture.","volume":"291","author":"Schett","year":"2004","journal-title":"JAMA"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00042192-201017010-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:36Z","timestamp":1786039716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201017010-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181ac0cc1","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}